POST Online Media Lite Edition


FTC settles charges in Boehringer Ingelheim-Sanofi deal

Staff Writer |
Following a public comment period, the Federal Trade Commission (FZC) has approved a final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Paris-based Sanofi would likely be anticompetitive.

Article continues below

First announced in December 2016, the FTC’s complaint alleged that as proposed, the swap would likely harm competition in the U.S. markets for various vaccines for companion animals, or pets, and certain parasite control products for cattle and sheep.

The order requires that Boehringer Ingelheim divest the canine, feline and rabies vaccines identified in the complaint to Eli Lilly and Company and its Elanco Animal Health division, and the parasite control products to Bayer AG.

What to read next

Sanofi and Boehringer will swap businesses
EC clears acquisition of Boehringer Ingelheim's business by Sanofi
Sanofi, Boehringer Ingelheim confirm closing of business swap